3, avenue des Tropiques
B.P. 305 - Les Ulis
11 articles with LFB S.A.
Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th, following Christian BÉCHON and Denis SOUBEYRAN’s departures.
LFB S.A. Announced Today The Acceptance By U.S. FDA Of The Filed Biologic License Application For Coagulation Factor VIIa Recombinant, (Eptacog Beta Activated)
First Marketing Authorizations In Europe For IQYMUNE, LFB S.A.’s 10% Liquid Intravenous Immunoglobulin
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors
LFB S.A. Announces That First Patient Has Begun Treatment With New Coagulation Factor VIIa (Recombinant) In Global Phase 3 Clinical Trial In Hemophilia A And B With Inhibitors
LFB S.A. Initiates Global Phase 3 Clinical Trial Of New Coagulation Factor Viia (Recombinant) In Patients With Hemophilia A And B
LFB S.A.'s Recombinant Anti-CD20 Monoclonal Antibody is Granted Orphan Drug Status in the USA for Chronic Lymphocytic Leukemia
GTC Biotherapeutics Announces Conversion of LFB S.A.'s Preferred Stock into Common Shares and Provides a Portfolio Update
The French Biopharmaceutical Group LFB S.A. Has Announced the First-in-Man Injections of Its First Two Therapeutic Monoclonal Antibodies and the Filing of BLAs for a New-Generation Immunoglobulin and a Fibrinogen